인쇄하기
취소

Hanmi Pharm signed an license agreement of new bio-drug with Janssen

Published: 2015-11-11 15:46:44
Updated: 2015-11-11 16:04:13

Hanmi Pharm(CEO Kwan-soon Lee) announced a license agreement to develop and commercialize HM12525A (LAPSGLP/GCG), a self-developed oxyntomodulin-based diabetes and obesity treatment, with Janssen on the 9th. Janssen is planning to have a phase 2 clinical trial of HM12525A in 2016.

HM12525A, a double-acting treatment which activates GLP-1, which secretes insulin and suppresses appetite, and Glu...

Fees

- Email service daily and homepage access.
  1. $300 per month.
  2. 5 Email holders per each company.
  3. Anual contract base.
Copyright Yakup.com All rights reserved.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.